05:24

Spesolimab mechanism of action in the treatment of generalized pustular psoriasis

02:31

Can new treatment garadacimab prevent attacks in patients with hereditary angioedema?

02:45

The BALATON/COMINO Trials: Study Overview and Week 24 Results

03:56

A video summary of the COLUMBUS 7 year update

02:33

Retinal vein occlusion

05:05

Elafibranor Efficacy and Safety in People with Primary Biliary Cholangitis

02:52

HERTHENA-Lung02: Phase III trial of patritumab deruxtecan in EGFR-mutated NSCLC post EGFR TKI

02:09

Analysis of patients’ side effects and quality of life in the ADAURA study

07:05

Evolution of the RebiSmart®3.0 Electromechanical Autoinjector

01:34

Tezepelumab for severe asthma: the PATHWAY and NAVIGATOR studies

14:52

Xevinapant + chemoradiotherapy in LA SCCHN: extended follow-up study

14:31

P-REALITY-X: Real-world, overall survival with palbociclib + aromatase inhibitor in HR+/HER2- MBC

02:00

Inhaled treprostinil in PH-ILD: The INCREASE study

11:52

Safety evaluation of empagliflozin for patients with type 2 diabetes and chronic kidney disease

01:47

Darolutamide in Black/African-American patients from ARAMIS

18:24

Prognostic value of evaluating MRD dynamics in multiple myeloma maintenance

11:24

Adalimumab biosimilar BI 695501 (Cyltezo®; adalimumab-adbm) in rheumatoid arthritis

06:34

Hedgehog inhibitors for basal cell carcinoma: real-world treatment patterns

13:20

A phase 3 study of biosimilar BI 695501 versus adalimumab in patients with Crohn’s disease - VJBM

13:37

Avelumab 1L Maintenance Treatment in Advanced Bladder Cancer: Practical Steps for Infusion Nurses

12:49

NRG1 fusion-driven tumors: biology, detection, and role of afatinib and other ErbB-targeting agents

02:49

The impact of flu and chickenpox vaccines in people with multiple sclerosis treated with cladribine

03:03

Propensity score matching methodology: why and how it is used

01:31

Nanoparticle surface-enhanced Raman spectroscopy as a tool to monitor hematological malignancy

01:42

Darolutamide and survival in mHSPC: a plain language summary of the ARASENS study

08:59

A pregnancy register cohort study among women with MS in Finland and Sweden

01:45

A qualitative research study in Japan investigating patients’ experience with mCRPC

05:21

TALAPRO-2 Phase III study design

11:53

INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC

14:35

Delaying loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy

09:35

Relapsing-remitting multiple sclerosis: the role of the patient in treatment decision-making

11:31

RodentSQL: a software suite for colony management of animal protocols

04:02

Mass spectrometry analysis in peptidomic research with Richard Kay

05:31

Benefits and challenges of assessing real-world genomics data with Bogi Eliasen

12:01

Real-world evidence generation with David Thompson

12:05

Re-challenging antibiotic resistance with Daniel Berman

10:03

Innovations in point of care testing for bacterial infections: The Longitude Prize

07:31

Outcomes of first-line pembrolizumab monotherapy for PD-L1–positive metastatic NSCLC

04:52

Burden of global deafness with Robin Youngs

07:07

Initiatives to combat global deafness with Robin Youngs

06:24

Pleomorphic xanthoastrocytoma: a brief review

08:58

Improving the analyses of progression-free survival from clinical trials for novel cancer treatments

01:48

The Drake Football Study

03:45

Orphan drug development and epilepsy with Ana Mingorance

07:27

Designing and developing therapeutic proteins with Jumi Shin

09:28

Clinical applications of nanomedicine research with Sourav Bhattacharjee

21:09

The promise of nanomedicine research with Sourav Bhattacharjee

08:47

Study of 693 NSCLC patients treated with afatinib

09:27

Post-hoc analysis of sequential afatinib and osimertinib in NSCLC patients

01:38

Vosoritide treatment accelerates bone growth in children with achondroplasia

11:22

Managing colorectal cancer patients in the COVID-19 era

01:38

The EXPLORER-HCM study: mavacamten for obstructive HCM

01:35

Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer

06:23

When should a primary care provider refer a patient with pustular psoriasis to a dermatologist?

11:35

Ixazomib-lenalidomide-dexamethasone in routine clinical practice

05:43

Antiracist patient engagement in adolescent and young adult oncology research and advocacy